Eli Lilly is allowing a limited number of adults with severe obesity to request early access to its experimental weight loss drug, retatrutide, through a compassionate use program. This pathway is reserved for patients who cannot join clinical trials and have exhausted standard treatment options for obesity-related complications, according to reporting by STAT.
Understanding the Retatrutide Compassionate Use Program
Compassionate use, or expanded access, provides a mechanism for patients with serious or life-threatening conditions to receive medications that have not yet received FDA approval. While obesity is associated with severe health risks, the FDA criteria for this program are stringent. According to criteria released by Eli Lilly, patients must meet several benchmarks to be considered for retatrutide:
Must be at least 18 years old.
Must be unable to participate in an active clinical trial.
Must have refractory obesity, meaning weight loss has not been achieved through lifestyle changes and standard treatments.
Must have at least two serious obesity-related complications, such as type 2 diabetes, high blood pressure, or heart disease.
Must have already discussed all standard treatment options with a physician.
Dr. Sun Kim, an endocrinologist at Stanford Health Care, notes that the requirement to have "discussed" all standard options remains somewhat ambiguous. She questions whether this necessitates that a patient must have failed those treatments or potentially even sought bariatric surgery before becoming eligible.
Clinical Trial Performance and Efficacy Data
Retatrutide: Eli Lilly's Game-Changing Weight Loss Drug – Early Access Explained!The high interest in retatrutide stems from its performance in phase 3 clinical trials. Unlike current GLP-1 medications, retatrutide targets three distinct hormone receptors: GLP-1, GIP, and glucagon. Data released by Eli Lilly shows that participants on the highest dose lost an average of 25 percent of their starting weight over 80 weeks, including those who dropped out of the study. When analyzing only those who remained on the treatment, that average increased to 28.3 percent. For comparison, previous pivotal trials for other weight loss medications showed lower average weight loss percentages over shorter durations:
Wegovy (semaglutide): Approximately 15 percent weight loss over 68 weeks.
Zepbound (tirzepatide): Nearly 21 percent weight loss over 72 weeks.
While these figures appear higher for retatrutide, experts caution that these drugs have not been tested in direct head-to-head clinical trials. Therefore, these figures do not definitively prove that retatrutide is more effective than currently approved options.
Current Availability and Access Barriers
As of August 2026, ClinicalTrials.gov lists only one trial actively recruiting for retatrutide, which focuses on patients with high-risk metabolic dysfunction-associated steatotic liver disease. Because there are few general obesity trials currently open, many patients lack a standard path to access the drug.According to the source, patients cannot apply directly for compassionate use; a treating physician must initiate the request, and the process requires authorization from both the FDA and an institutional review board.Dr. Yuval Pinto, an obesity and family medicine doctor at Johns Hopkins Medicine, suggests that while he would consider this a last resort for patients who have tried everything else, he would not prioritize it as a first-line treatment. The lack of full FDA approval means that safety data is still being gathered, and Lilly has not yet clarified how long treatment would continue or who would cover the costs of the required medical monitoring.
Risks of Unapproved Alternatives
Medical professionals warn against seeking retatrutide through compounding pharmacies or online "research" chemical suppliers. Dr. Kim emphasizes that these products carry significant risks, including improper dosing, potential contaminants, or the inclusion of entirely different ingredients. The sale of compounded retatrutide is currently illegal, and patients are urged to avoid any source that is not a regulated clinical trial or an authorized compassionate use program.
Frequently Asked Questions
Can I apply for retatrutide compassionate use on my own?
No. A treating physician must support the request and contact Eli Lilly directly to begin the formal application process.Who qualifies for this program?
Eligibility is restricted to adults with refractory obesity and at least two serious obesity-related complications who have exhausted standard treatment options and cannot access a clinical trial.Is retatrutide more effective than Zepbound or Wegovy?
While clinical trial data for retatrutide shows high percentages of weight loss, there have been no direct head-to-head studies comparing it to Zepbound or Wegovy, so direct efficacy comparisons cannot be confirmed.When will retatrutide be available to the public?
FDA approval for retatrutide is not expected until sometime next year.Are you interested in the latest developments in metabolic health and clinical research? Subscribe to our newsletter for updates on emerging medical treatments.
